- 11/26/2007 - VasoGenix Pharmaceuticals presents data related to CGRP for heart failure patients at AHA meeting.
LENEXA, Kan.--(BUSINESS WIRE)--VasoGenix Pharmaceuticals Inc. (www.vasogenix.net) recently announced the results of collaborative research that the Company conducted with the Cleveland Clinic’s Lerner Research Institute related to VasoGenix’s first drug, Calcitonin Gene Related Peptide (‘CGRP’), for the treatment of heart failure. The data was presented earlier this month at the Annual Meeting of the American Heart Association in Orlando, Florida. The presentation was entitled: Calcitonin Gene Related Peptide Receptor Regulation in Human Heart Failure. The research was conducted in the laboratory of Sathyamangla V. Naga Prasad, Ph.D., at Cleveland Clinic’s Lerner Research Institute.
Study results demonstrated that CGRP receptors in heart tissue of heart failure patients are upregulated 38% compared to heart tissue taken from patients without heart failure. Furthermore, the study elucidated the regulation of CGRP receptor components in human heart failure and evaluated the signaling mechanisms involved in CGRP receptor activation.
- 9/7/2005 - VasoGenix Pharmaceuticals Announces Formation of Cardiology Research Steering Committee
VasoGenix Pharmaceuticals Announces Formation of Cardiology Research Steering Committee Through the Cleveland Clinic
- 4/11/2005 - VasoGenix and QLT to Develop Major New Treatment for Congestive Heart Failure
VasoGenix and QLT to Develop Major New Treatment for Congestive Heart Failure
- 11/4/2004 - VasoGenix completes Series B preferred stock offering
VasoGenix Pharmaceuticals, Inc. has completed the Series B preferred stock offering and raised just over $1 million.
- 10/28/2004 - VasoGenix sponsored research presented at AHA Scientific Sessions
Calcitonin Gene Related Peptide (CGRP) in protecting oxygen deprived cardiac cells.